Professor of Medicine, Georgetown University
Oncology
Dr. Louis M. Weiner, MD
|
|
Give Review
Louis Weiner works in the field of Oncology. He researched medicine at Icahn School of Medicine at Mount Sinai. Icahn School of Medicine at Mount Sinai has a rank of 20 in research and a 62 in primary care He received 6 awards: "America's Top Doctors", "America's Top Doctors for Cancer", "Top Doctors:Washington DC Area", "Top Doctors:Washington-Baltimore", "Philadelphia Magazine" and "Whos Who in Medicine and Healthcare". Doctor Louis M. Weiner, MD is a published doctor and has 63 publications published. The lastest was: 'Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer.' Louis Weiner accepts Medicare payments and is registered with Medicare.gov.
Publications
- Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic Cancer.
- Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic Cancer.
- Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7-10, 2015, San Diego, CA.
- Beyond peptides and mAbs-current status and future perspectives for biotherapeutics with novel constructs.
- Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced Malignancies.
- c-Abl Modulates Tumor Cell Sensitivity to Antibody-Dependent Cellular Cytotoxicity.
- IL4 Limits the Efficacy of Tumor-Targeted Antibody Therapy in a Murine Model.
- Antibody engineering and therapeutics conference.
- The development of immunoconjugates for targeted Cancer therapy.
- Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy.
- The Clinical Potential of Targeted Nanomedicine: Delivering to Cancer Stem-like Cells.
- Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens.
- Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation.
- Monoclonal antibodies for the treatment of Cancer.
- Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment.
- Dynamic modelling of oestrogen signalling and cell fate in breast Cancer cells.
- Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid Tumors.
- Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic Pancreatic adenocarcinoma.
- Supportive treatments for oncology patients: not just icing on the cake.
- Vaccine prevention of Cancer: can endogenous antigens be targeted?
- Synthetic lethal screen of an EGFR-centered network to improve targeted therapies.
- The prioritization of Cancer antigens: a national Cancer institute pilot project for the acceleration of translational research.
- Monoclonal antibodies for Cancer immunotherapy.
- Fibroblast activation protein and its relationship to clinical outcome in Pancreatic adenocarcinoma.
- Cancer immunotherapy--the endgame begins.
- Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-Lymphoma therapy.
- From the Guest Editor: Monoclonal antibodies have emerged as versatile and useful Cancer therapeutics.
- Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid Tumors.
- Dose and schedule study of panitumumab monotherapy in patients with advanced solid Malignancies.
- Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic coloRectal cancer.
- Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with Esophageal carcinoma.
- Monoclonal antibodies in therapy of solid Tumors.
- Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics.
- Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen.
- Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast Cancer (E3194): a trial co...
- Antibody constructs in Cancer therapy: protein engineering strategies to improve exposure in solid tumors.
- Phase II trial of preoperative chemoradiation with a hyperfractionated radiation boost in locally advanced Rectal cancer.
- A review of antibody therapeutics and antibody-related technologies for oncology.
- Isolation and characterization of circulating tumor cells in patients with metastatic coloRectal cancer.
- Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers.
- InDuction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal ca...
- Fully human therapeutic monoclonal antibodies.
- Isolation of scFvs to in vitro produced extracellular domains of EGFR family members.
- Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in coloRectal cancer.
- Monoclonal antibody therapy of Cancer.
- Global gene expression profiling of circulating tumor cells.
- Tunable antibodies.
- Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth.
- Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format.
- A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice.
- Phase II randomized study of vaccine treatment of advanced prostate Cancer (E7897): a trial of the Eastern Cooperative Oncology Group.
- Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.
- Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936.
- Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable Esophageal carcinoma: a pha...
- The rollercoaster ride to anti-Cancer antibodies.
- Tumors and their microenvironments: tilling the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation study of sibrotuzumab in patients with advanced or m...
- Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic Pancreatic adenocarcinoma.
- Monoclonal antibody therapy for Cancer.
- Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model.
- Beyond neutrophil recovery: manipulation of the tumor microenvironment by GM-CSF to control Cancer.
- Recurrence of Early Stage Colon Cancer Predicted by Expression Pattern of Circulating microRNAs.
- Platform for Personalized Oncology: Integrative Analyses reveal novel molecular signatures associated with colorectal cancer relapse.
Schools
Mount Sinai School of Medicine
Fletcher Allen Health Care
New England Med Center Hosps
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Select
- Blue Card PPO
- Blue Choice Advantage
- Blue Choice Network POS
- Blue Preferred PPO
- CareFirst Maryland POS
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care of Delaware PPO
- First Health (Coventry Health Care) PPO
- Kaiser Permanente
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Top Doctors:Washington DC Area
- Top Doctors:Washington-Baltimore
- Philadelphia Magazine
- Whos Who in Medicine and Healthcare
Education
-
Tufts Medical Center -
University of Vermont - Fletcher Allen Health Care -
Icahn School of Medicine at Mount Sinai
Hospital
-
MedStar Georgetown University Hospital
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1205859931 |
| Last Name Of The Provider | WEINER |
| First Name Of The Provider | LOUIS |
| View All |
Similar Doctors
|
|
Dr. Laleh Amiri-Kordestani, MD |
|
|
Dr. John L. Marshall, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paula R. Pohlmann, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul G. Kluetz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adrianne P. Kelly, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julia A. Beaver, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brandon G. Smaglo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Catherine M. Broome, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Channing Paller, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey K. Klotz, MD
This Doctor is OpenDoctor Recommended.
|